Editorial Comment: Morbimortality in diabetic patients is still a matter of deep concern in the context of reduced cardiovascular mortality of recent years. Based on the proven clinical benefit of drugs such as ACEIs or ARBs in treating patients with renal failure, the study randomized 8700 treated with aliskiren or placebo, in a 32 month follow up scheme. No differences were observed in the composite cardio-renal end points, neither when CV and renal end points were observed individually.
Hans Henrik Parving
2012-08-25
Original title: ALTITUDE: Aliskiren Trial In Type 2 Diabetes Using cardio-renal Endpoints
